EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia

Heng Shen iD, Jiayuan Chen, Xiaoyuan Gong, Chunlin Zhou, Dong Lin, Kaiqi Liu iD, Benfa Gong, Guangji Zhang, Yan Li, Yuntao Liu, Shaowei Qiu, Bingcheng Liu und 5 weitere

Cancers · 27.01.2026 · 18 (3) · 401

DOI: 10.3390/cancers18030401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 27.01.2026. Verfasst von Heng Shen und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

KMT2A rearrangements are a frequent genetic abnormality associated with Acute myeloid leukemia (AML), historically linked to varied prognoses and outcomes. The prognosis for patients with this rearrangement remains controversial, necessitating further research to stratify risk and guide treatment.

Methods

In this retrospective study, a total of 3468 adolescent and adult AML patients were screened, and 181 patients harboring KMT2A rearrangements were analyzed. We used FISH, RT-PCR, and next-generation sequencing, including transcriptome and targeted panels, for diagnosis and mutation profiling. All patients received intensive chemotherapy. We evaluated overall survival and event-free survival using Kaplan–Meier and Cox regression models, with HSCT analyzed as a time-dependent variable.

Results

The incidence of KMT2A-rearranged AML in our newly diagnosed cohort was 5.9%. Among the 181 patients included in the final analysis, 89 (49.2%) were male and 92 (50.8%) were female, with a median age of 33 years (range: 13–65). The distribution of fusion partners included KMT2A::MLLT3 (n = 39), KMT2A::AFDN (n = 27), KMT2A::MLLT10 (n = 25), KMT2A::ELL (n = 24), and others (n = 12). Seventy-four patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1). The median follow-up for survivors was 17.53 months (range 1.47–112.57), and the 3-year overall survival (OS) and event-free survival (EFS) for the entire cohort were 42.0% and 32.1%, respectively. Patients with KMT2A::ELL exhibited superior OS compared to other subtypes (3-year OS [ELL vs. non-ELL]: 59.8% vs. 39.3%, p = 0.023). Concomitant mutations did not significantly impact the prognosis of KMT2A-rearranged AML patients. In multivariate analysis, age and HSCT in CR1 were independently associated with OS and EFS (OS: HR = 1.022, p = 0.026 [age]; HR = 0.238, p < 0.001 [HSCT]; EFS: HR = 1.027, p = 0.002 [age]; HR = 0.155, p < 0.001 [HSCT]). Patients aged over 20 years were more likely to benefit from HSCT than those aged 20 years or younger (p < 0.001 [age > 20], p = 0.780 [age ≤ 20]).

Conclusions

Our study revealed the heterogeneous outcomes of KMT2A-rearranged AML patients and clarified the impact of HSCT across different age groups.

Schlagwörter

Stichwörter der Autor:innen

KMT2A rearrangementacute myeloid leukemiaclinical outcomeshematopoietic stem cell transplantation

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin 301600, China.

ORCID-Profile: Heng Shen, Kaiqi Liu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • Tian Jin Natural Science Foundation
  • Haihe Laboratory of Cell Ecosystem Innovation Fund
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Shen, H., Chen, J., Gong, X., Zhou, C., Lin, D., Liu, K., Gong, B., Zhang, G., Li, Y., Liu, Y., Qiu, S., Liu, B., Wang, Y., Mi, Y., Fang, Q., Wang, J., & Wei, H. (2026). Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia. Cancers, 18(3), 401. https://doi.org/10.3390/cancers18030401

Vancouver

Shen H, Chen J, Gong X, Zhou C, Lin D, Liu K, et al. Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia. Cancers. 2026;18(3):401. doi:10.3390/cancers18030401

BibTeX
@article{Shen2026,
  author = {Shen, Heng and Chen, Jiayuan and Gong, Xiaoyuan and Zhou, Chunlin and Lin, Dong and Liu, Kaiqi and Gong, Benfa and Zhang, Guangji and Li, Yan and Liu, Yuntao and Qiu, Shaowei and Liu, Bingcheng and Wang, Ying and Mi, Yingchang and Fang, Qiuyun and Wang, Jianxiang and Wei, Hui},
  title = {Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {401},
  doi = {10.3390/cancers18030401}
}
Kostenlos starten →